Adrenalectomy for Solitary Adrenal Gland Metastases

NCT01135238 | Completed DMC

• 1 other identifier: 09-007747
• Study Type: observational
• Target: 168
• Locations: 0 countries
• Sites: N/A

Brief Summary

The adrenal glands are one of the most common organs involved in metastatic disease. Metastases are the second most common type of adrenal mass, second only to adenomas. It is a frequent finding during autopsy with a reported rate as high as 27% in patients with known primary malignancy. Although several studies have found an increased survival in patients who undergo resection of solitary adrenal metastases the indications for adrenalectomy in cases of metastatic adrenal tumor remain controversial. Collinson et al reported an increased survival in patients with melanoma. Median survival was 16 months for patients who underwent adrenalectomy compared to 5 months for patients with documented adrenal metastases treated non surgically. The aim of this study is to compare retrospectively in case and control study, performing adrenalectomy, open or laparoscopic, versus supportive treatment for patients with solitary adrenal gland metastases. The investigators will review charts of patients between January 1994 and November 2009 who had adrenal gland metastases. The variables the inevstigators will compare are mortality, morbidity, primary tumour sites, histological cell type, age, tumour size, presence of synchronous metastases, mean time from diagnosis of primary tumor to treatment of adrenal metastases, indication for adrenalectomy, partial versus total adrenalectomy, suspected versus confirmed metastatic disease.

Conditions

Adrenal Gland Metastases; Adrenalectomy

Keywords

adrenalectomy; metastasis; morbidity; mortality; survival

Outcome Measures

Primary Outcomes (1)

• Adrenalectomy improves overall survival in patients with solitary metastasis

  Survival data compared to historic controls

  25 years

Secondary Outcomes (1)

• Adrenalectomy can be performed with minimal morbidity in patients with metastatic lesions to the adrenal gland.

  25 years

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients undergoing adrenalectomy for metastatic disease.

You may qualify if:

• Metastatic disease to the adrenal gland

You may not qualify if:

• Primary adrenal neoplasm

Sponsors & Collaborators

• Mayo Clinic: lead

MeSH Terms

Conditions

Neoplasm Metastasis

Condition Hierarchy (Ancestors)

Neoplastic Processes; Neoplasms; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Melanie L Richards, MD

  Mayo Clinic

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: June 1, 2010
• First Posted: June 2, 2010
• Study Start: November 1, 2009
• Primary Completion: November 1, 2010
• Study Completion: November 1, 2010
• Last Updated: December 16, 2011

Record last verified: 2011-12